To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Carlyle and Hellman poised for $3.9bn take-private
The firms’ $3.9bn acquisition of Pharmaceutical Product Development will be one of the largest recent deals in a hot healthcare and pharmaceutical market.
